The 12 most recent market catalysts affecting $CDNA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 75
CareDx shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $60 to $74.
This headline represents a strong positive corporate catalyst for CareDx (CDNA). The maintained 'Buy' rating, coupled with a 23% increase in the price target, indicates that a prom…
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on CareDx, Raises Price Target to $74
BTIG analyst Mark Massaro maintained a 'Buy' rating for CareDx (CDNA) and raised the price target from $60 to $74. This action signals increased confidence from a prominent analyst…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 65
Canaccord Genuity Initiates Coverage On CareDx with Buy Rating, Announces Price Target of $65
Canaccord Genuity analyst Kyle Mikson has initiated coverage on CareDx (CDNA) with a 'Buy' rating and a $65 price target. This event is significant for CareDx as new analyst covera…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
BTIG Maintains Buy on CareDx, Raises Price Target to $60
BTIG analyst Mark Massaro has maintained a 'Buy' rating for CareDx (CDNA) and significantly raised the price target from $45 to $60. This upward revision in the price target signal…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 85
CareDx shares are trading higher after the company reported better-than-expected Q2 financial results. Also, the company raised its FY2026 sales guidance above estimates.
This headline represents a strong corporate catalyst for CareDx, as positive earnings surprises and upward revisions to future guidance are typically met with significant investor …
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 85
CareDx shares are trading higher after the company reported better-than-expected Q2 financial results. Also, the company raised its FY2026 sales guidance above estimates.
This headline is a strong positive corporate catalyst for CareDx (CDNA). Better-than-expected Q2 results demonstrate current operational strength, while raising FY2026 sales guidan…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 92
CareDx Q2 Adj. EPS $0.37 Beats $0.23 Estimate, Sales $131.948M Beat $114.044M Estimate
CareDx reported Q2 adjusted EPS of $0.37, significantly beating the $0.23 estimate, and sales of $131.948 million, surpassing the $114.044 million estimate. This represents a subst…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
CareDx Raises FY2026 Sales Guidance from $447.000M-$465.000M to $490.000M-$500.000M vs $455.924M Est
CareDx (CDNA) has updated its financial projections, raising its FY2026 sales guidance from an initial range of $447 million-$465 million to a new range of $490 million-$500 millio…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 65
BTIG Maintains Buy on CareDx, Raises Price Target to $45
BTIG analyst Mark Massaro has maintained a 'Buy' rating on CareDx (CDNA) and raised the price target from $28 to $45. This action indicates a strong vote of confidence from a promi…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
CareDx shares are trading higher after the company announced the finalization of the Medicare Local Coverage Determination process related to molecular testing for solid organ allograft rejection.
This headline is a significant positive catalyst for CareDx (CDNA) as the finalization of Medicare Local Coverage Determination (LCD) for molecular testing for solid organ allograf…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 75
CareDx Finalizes Medicare Local Coverage Determination Procedure Regarding Molecular Testing For Solid Organ Allograft Rejection
CareDx announced the finalization of the Medicare Local Coverage Determination (LCD) process for its molecular testing services used to detect solid organ allograft rejection. This…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.